# Michele Bauer

> Michele Bauer is a Series A investor at Medicxi (Geneva) backing Therapeutics and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Medicxi](https://shizune.co/investors/profile/medicxi-ventures)
- Location: Geneva, Switzerland
- Total investments: 3
- Last investment: Sep 2020
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/mich%C3%A8le-ollier-3b438a6
- X (Twitter): https://twitter.com/MicheleOllier
- Website: https://x.com/MicheleOllier

Michele Bauer is a Series A investor at Medicxi in Geneva focused on Therapeutics and Biotechnology. Michèle Ollier is the Partner at Index Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Funding Round | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Palladio Biosciences | Palladio Bio is a clinical-stage company developing transformative medicines for orphan diseases of the kidney. The company specializes in the fields of biotechnology, pharmaceutical. and therapeutics. Its products are designed for renal disease, kidney disease, and polycystic kidney disease.The company was founded in 2015 and headquartered inHorsham, Pennsylvania. | $20M | Series B | Sep 25, 2020 |  |
| Diasome Pharmaceuticals | Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products forpatients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania. | $30M |  |  |  |
| Palladio Biosciences | Palladio Bio is a clinical-stage company developing transformative medicines for orphan diseases of the kidney. The company specializes in the fields of biotechnology, pharmaceutical. and therapeutics. Its products are designed for renal disease, kidney disease, and polycystic kidney disease.The company was founded in 2015 and headquartered inHorsham, Pennsylvania. |  | Series A |  |  |

3 of 3 investments shown.

## Co-investors
- [JDRF T1D Fund](https://shizune.co/investors/profile/jdrf-t1d-fund) — VC Fund, 1 deal together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 1 deal together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 1 deal together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 1 deal together

## About Medicxi

VC Fund · London, United Kingdom

Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

5 contacts available at Medicxi.

| Name | Title | Profile |
| --- | --- | --- |
| Giovanni Pericolini | Finance Director & CFO | https://shizune.co/investors/profile/giovanni-pericolini |
| Kevin Johnson | Co-Founder & Partner | https://shizune.co/investors/profile/kevin-johnson-8 |
| Mark Boer | Member of the Board of Advisors | https://shizune.co/investors/profile/mark-de-boer |
| Michele Bauer | Co-Founder & Partner | https://shizune.co/investors/profile/michele-ollier |
| Trevor Baglin | Venture Partner | https://shizune.co/investors/profile/trevor-baglin |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Michele Bauer invest in?

Michele Bauer invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michele Bauer last invest?

The most recent investment recorded for Michele Bauer closed in Sep 2020. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co